{"nctId":"NCT00557245","briefTitle":"Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples","startDateStruct":{"date":"2008-05"},"conditions":["HIV-1 Infections","HIV Infections"],"count":4758,"armGroups":[{"label":"Tenofovir Disoproxil Fumarate (TDF)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Tenofovir Disoproxil Fumarate (TDF)"]},{"label":"Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Tenofovir Disoproxil Fumarate (TDF)","otherNames":["Viread + Placebo Truvada"]},{"name":"Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)","otherNames":["Truvada + Placebo Viread"]},{"name":"Placebo","otherNames":["Placebo + Placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria for HIV-1 uninfected partner:\n\n* Partner within an HIV-1 discordant heterosexual relationship\n* One partner meets study eligibility for HIV-1 uninfected study participant and the other partner meets study eligibility criteria for HIV-1 infected participant\n* Plan to remain in the relationship for the duration of the study period\n* Adequate renal, hepatic \\& hematologic function\n* Negative Hepatitis B surface antigen test\n* Willing and able to provide written informed consent \\& locator information\n\nExclusion Criteria for HIV-1 uninfected partner:\n\n* Current pregnancy, or planning to become pregnant during the study period\n* Currently breastfeeding\n* Concurrent enrollment in another HIV-1 vaccine or prevention trial\n* Receiving ongoing antiretroviral therapy\n* Repeated positive urine dipstick tests for glycosuria or proteinuria\n* Active and serious infections\n* History of pathological bone fractures not related to trauma\n\nInclusion Criteria for HIV-1 infected partner:\n\n* Partner within an HIV-1 discordant heterosexual relationship\n* One partner meets study eligibility for HIV-1 uninfected study participant and the other partner meets study eligibility criteria for HIV-1 infected participant\n* HIV-1 infected based on positive EIA\n* No history of any clinical AIDS-defining diagnoses\n* Plan to remain in the relationship for the duration of the study period\n* Willing and able to provide written informed consent \\& locator information\n\nExclusion Criteria for HIV-1 infected partner:\n\n* Current use of antiretroviral therapy\n* Concurrent enrollment in another HIV-1 treatment trial","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of HIV-1 Seroconversion Among HIV-1 Uninfected Participants","description":"The efficacy of once daily PrEP in preventing HIV-1 acquisition among uninfected heterosexuals in HIV-1 discordant partnerships, measured by calculating the HIV incidence per 100 person-years in each of three arms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.65","spread":null},{"groupId":"OG001","value":"0.50","spread":null},{"groupId":"OG002","value":"1.99","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Serious Adverse Events (SAEs)","description":"Safety of daily TDF or FTC/TDF among HIV-1 uninfected individuals randomized to TDF or FTC/TDF compared to those randomized to placebo measured as the number of participants with Serious Adverse Events (SAEs) during follow-up.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"118","spread":null},{"groupId":"OG001","value":"115","spread":null},{"groupId":"OG002","value":"118","spread":null}]}]}]},{"type":"SECONDARY","title":"Study Drug Adherence: Total Number of Study Drug Doses Taken of the Total Dispensed Doses.","description":"Adherence to study medication as assessed by pill count at follow-up visits. We assessed the total number of doses taken of the total dispensed doses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"97","spread":null},{"groupId":"OG002","value":"97","spread":null}]}]}]},{"type":"SECONDARY","title":"Study Drug Adherence: Self-reported Missed Doses of Study Drug","description":"Adherence to study drug measured as the percentage of visits when participants reported missing 1) any dose of study drug in the prior month and 2) 2 or more consecutive doses of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Seroconverters With an HIV-1 Mutation Conferring Resistance to TDF or FTC","description":"HIV-1 resistance as measured by the number of seroconverters who had an HIV-1 reverse transcriptase mutation (K65R, K70E, M184I, or M184V) conferring resistance to TDF or FTC. These mutation types were pre-defined. Plasma samples for resistance testing were collected at the visit seroconversion was first detected and again at a visit within 1 month of seroconversion. Mutations detected at either of those visits are reported.\n\nBoth seroconverters found to have a resistance mutation had been HIV infected at enrollment (TDF arm: n=1; FTC-TDF arm: n=1).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Sexually Transmitted Infection (STI) During Follow-up","description":"Prevalence of STIs measured as the number of participants with a positive test result for N. gonorrhoeae, C. trachomatis, or T. vaginalis during follow-up. Participants were tested for STIs at annual follow-up visits and at intervening visits at which the participant presented with symptoms of an STI. Assessment for symptomatic sexually transmitted infections was conducted quarterly.\n\nN. gonorrhoeae and C. trachomatis testing were by APTIMA Combo 2 (Gen-Probe) or COBAS Amplicor (Roche Diagnostics). T. vaginalis testing was by APTIMA TV TMA (Gen-Probe) or In Pouch TV (Biomed Diagnostics).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"76","spread":null},{"groupId":"OG002","value":"85","spread":null}]}]}]},{"type":"SECONDARY","title":"Prevalence of Unprotected Sex During Follow-up","description":"Sexual risk behavior of participants, measured as the percentage of visits when participants reported having unprotected sex during follow-up.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Congenital Abnormalities Among Infants Born to Female Participants Taking Study Drug.","description":"Infant outcomes measured as the number of live-born infants born to female participants taking study drug that had any congenital anomalies.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Length Among Infants Born to Female Participants Taking Study Drug","description":"The slope of the linear model of the growth of infants (length) during the entirety of follow-up. The length of the infant was measured as a z-score, in terms of standard deviations from the age and gender specific median using the World Health Organization growth curve, accounting for skewness. The slope, representing the change over time of the z-score, was calculated using all available z-scores over 12 months and regressing against study month.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.006","spread":null},{"groupId":"OG001","value":"0.036","spread":null},{"groupId":"OG002","value":"-0.033","spread":null}]}]}]},{"type":"SECONDARY","title":"Weight Among Infants Born to Female Participants Taking Study Drug","description":"The slope of the linear model of the growth of infants (weight) during the entirety of follow-up. The weight of the infant was measured as a z-score, in terms of standard deviations from the age and gender specific median using the World Health Organization growth curve, accounting for skewness. The slope, representing the change over time of the z-score, was calculated using all available z-scores over 12 months and regressing against study month.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.021","spread":null},{"groupId":"OG001","value":"0.009","spread":null},{"groupId":"OG002","value":"-0.056","spread":null}]}]}]},{"type":"SECONDARY","title":"Head Circumference Among Infants Born to Female Participants Taking Study Drug","description":"The slope of the linear model of the growth of infants (head circumference) during the entirety of follow-up. The head circumference of the infant was measured as a z-score, in terms of standard deviations from the age and gender specific median using the World Health Organization growth curve, accounting for skewness. The slope, representing the change over time of the z-score, was calculated using all available z-scores over 12 months and regressing against study month.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.057","spread":null},{"groupId":"OG001","value":"-0.005","spread":null},{"groupId":"OG002","value":"-0.079","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":118,"n":1584},"commonTop":["NEUTROPHIL COUNT DECREASED","BLOOD PHOSPHORUS DECREASED","MALARIA","HAEMOGLOBIN DECREASED","PLATELET COUNT DECREASED"]}}}